MSH|^~\&|IGENE|MFT|EPIC|MFT|20251014155942||ORU^R01|ORIE-251014-9|T|2.3PID||9737383281|ABC14567^^^R0A^MR||CONGLETON^Margaery||19820211|F|||^^^^CW12 1BNORC|RE|LRI-1601716017|||||||||||||||||||Manchester University NHS Foundation Trust^^^^^R0A^^^ODSOBR|1|LRI-1601716017|Gen825750-LRI1|42318-6^GALT gene targeted mutation analysis^LN|R|201608030830|201608091650|OBX|1|TX|53577-3^Reason for study^LN|1|Patient may be carrier for classic galactosemia.|OBX|2|CWE|51967-8^Genetic disease(s) assessed^LN|1|C0016952^Galactosemia^MedGen-Dis|OBX|3|CWE|51958-7^Transcript reference sequence [Identifier]^LN|1|NM_000249^NM_000249^RefSeq-T|OBX|4|CNE|48018-6^Gene studied [ID]^LN|1.a|4135^GALT^HGNC-Symb|OBX|5|CWE|36908-2^Gene mutations tested^LN|1.a|-119_-116delGTCA^-119_-116delGTCA^HGVS.c|OBX|6|CWE|36908-2^Gene mutations tested^LN|1.b|Asp98Asn^Asp98Asn^HGVS.p|OBX|7|CWE|36908-2^Gene mutations tested^LN|1.c|Gln188Arg^Gln188Arg^HGVS.p|OBX|8|CNE|51968-6^Discrete variation analysis overall interpretation^LN|1|LA6576-8^Positive^LN|OBX|9|FT|51969-4^Full narrative report^LN|1|Result Summary-Positive\.br\\.br\ Result â€“ The following heterozygous alteration was identified: Amino Acid change: p.Q188R (Gln188Arg). DNA change: c.563A>G (g.34648167), Classification: PATHOGENIC \.br\\.br\ Interpretation - Biochemical and molecular test results are in agreement. The observed GALT enzyme activity in red blood cells (12.2 nmol/h/mg Hb) and the presence of a single copy of p.Q188R suggest that this individual is a carrier of classic galactosemia. This individual should not be at risk for developing symptoms related to this disorder; however, he or she may be at risk for having offspring with galactosemia. If appropriate, enzymatic and molecular studies for this individual's reproductive partner are recommended to further clarify this risk. \.br\\.br\ Method - A multiplex PCR-based assay was used to test for the presence of the following mutations in the GALT gene.|OBX|10|CWE|62374-4^Human reference sequence assembly^LN|1|LA14029-5^GRCh37^LN|OBX|11|NM|82115-7^dbSNP version^LN|1|147|Attributes of Discrete Genetic Variants: Report Section 2OBX|12|CNE|83005-9^Variant Category^LN|2a|LA26801-3^Simple Variant^LN|OBX|13|CNE|81252-9^Discrete genetic variant^LN|2a|3614^NM_000155.3(GALT):c.563A>G(p.Gln188Arg)^ClinVar-V|OBX|14|CWE|48018-6^Gene studied^LN|2a|3614^GALT^HGNC-Symb|OBX|15|CWE|51958-7^Transcript RefSeq ID^LN|2a|NM_000155.3^NM_000155.3^RefSeq-T|OBX|16|CWE|41103-3^Transcript DNA Change (cHGVS)^LN|2a|c.563A>G^c.563A>G^HGVS.c|OBX|17|CWE|48005-3^Amino acid change p.HGVS^LN|2a|p.Gln188Arg^p.Gln188Arg^HGVS.p|OBX|18|CWE|48019-4^DNA change type^LN|2a|LA6690-7^Substitution^LN|OBX|19|CWE|48006-1^Amino Acid change type|2a|LA6698-0^Missense^LN|OBX|20|CWE|48013-7^Genomic reference sequence^LN|2a|NG_009029.1:g.6533A>G^NG_009029.1:g.6533A>G^RefSeq-G|OBX|21|CWE|81290-9^Genomic DNA change(gHGVS)^LN|2a|NC_000009.11:g.34648167A>G^NC_000009.11:g.34648167A>G^HGVS.g|OBX|22|ST|69547-8^Genomic ref allele^LN|2a|A|OBX|23|NR|81254-5^Genomic allele start-end^LN|2a|34648167^34648167|OBX|24|ST|69551-0^Genomic alt allele^LN|2a|G|OBX|25|CNE|81255-2^dbSNP ID^LN|2a|rs75391579^rs75391579^dbSNP|OBX|26|CWE|48001-2^Cytogenetic (chromosome) location^LN|2a|9p13^9p13^Chrom-Loc|OBX|27|CNE|48002-0^Genomic source class^LN|2a|LA6683-2^Germline^LN|OBX|28|CNE|81304-8^Variant analysis method type^LN|2a|LA26418-6^PCR^LN|OBX|29|CNE|53037-8^Genetic variation clinical significance^LN|2a|LA6668-3^Pathogenic^LN|OBX|30|CNE|69548-6^Genetic variant assessment^LN|2a|LA9633-4^Present^LN|OBX|31|CWE|81259-4^Probable associated phenotype^LN|2a|C0268151^Deficiency of UDPglucose-hexose-1-phosphateuridylyltransferase^MedGen-Dis|Allelic state/phase informationOBX|32|CNE|53034-5^Allelic state^LN|2a|LA6706-1^Heterozygous^LN|